Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph II Regn2810, W/ Basal Cell Ca Progression On Hedgehog Pathway Inhibitor Therapy

Protocol: OSU-17172

Full Title

A Phase II Study Of Regn2810, A Fully Human Monoclonal Antibody To Programmed Death-1, In Patients With Advanced Basal Cell Carcinoma Who Experienced Progression Of Disease On Hedgehog Pathway Inhibitor Therapy, Or Were Intolerant Of Prior Hedgehog Pathway Inhibitor Therapy

Skin Cancers Basal Cell Carcinoma